Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020007522
Abstract: In this phase 2 multicenter study (NCT01816971), we evaluated incorporation of autologous stem cell transplant (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4… read more here.
Keywords: cycles krd; carfilzomib lenalidomide; newly diagnosed; multiple myeloma ... See more keywords